On July 16, 2026, the European Centre for Disease Prevention and Control (ECDC) published a risk assessment that news outlets across Europe picked up on July 20. Gonococcal strains resistant to ceftriaxone, the first-line antibiotic, are no longer only imported. They are now spreading inside Europe itself.
For a patient, the meaningful change is not epidemiological. It is written on the laboratory report. A result that says “gonorrhea detected” no longer tells the whole story. Here is what shifts, line by line.
What the ECDC actually said
The agency reviewed reports from 11 countries since 2022: Austria, Croatia, Denmark, France, Germany, Ireland, the Netherlands, Norway, Spain, Sweden and the United Kingdom. Two findings stand out.
First, case counts are climbing. More than 106,000 confirmed gonorrhea cases were recorded across the EU and EEA in 2024, the highest figure since European surveillance began in 2009.
Second, and more concerning: some resistant infections occurred in people who had not traveled. That is the signature of local transmission. The ECDC still rates the overall risk as low for the general sexually active population, and higher for people having sex without protection with new, casual or multiple partners.
Csaba Ködmön, an ECDC microbiology expert, framed the response around three levers: stronger prevention, expanded antimicrobial testing, and timely diagnosis. That middle one is the part that reaches your lab report.
Why your report does not tell you everything
A NAAT answers yes or no, never which antibiotic
Almost all gonorrhea screening today relies on a nucleic acid amplification test, or NAAT. The lab looks for bacterial DNA in a urine, vaginal, rectal or throat sample.
It is fast, highly sensitive, and it works at sites where the organism is hard to grow, such as the pharynx. But a NAAT has a structural limit: it detects DNA, not a living organism. It cannot tell you whether the antibiotic will work. The same interpretive gap applies elsewhere in the lab, as our guide to procalcitonin as an infection marker explains: a detected signal is not an interpreted one.
Culture and susceptibility testing matter again
To learn whether a strain is susceptible or resistant, the lab has to grow the bacteria. That is culture. Then it exposes the isolate to a panel of antibiotics. That is antimicrobial susceptibility testing. The logic mirrors a stool culture or a urine culture: identify the organism first, then measure how vulnerable it is.
| On your report | NAAT (PCR) | Culture plus susceptibility |
|---|---|---|
| What it answers | Gonorrhea present or absent | Which antibiotics still work |
| Turnaround | 24 to 48 hours | 3 to 5 days |
| Sample | Urine, vaginal, rectal, throat | Dedicated swab, rapid transport |
| Detects resistance | No, unless a dedicated resistance PCR is used | Yes |
So if your clinician orders a culture in addition to the NAAT, that is not duplication. It is the only way to see resistance coming.
Reading the ceftriaxone MIC
One number dominates a gonococcal susceptibility report: the MIC, or minimum inhibitory concentration. It is the smallest antibiotic dose that stops the bacteria from growing, expressed in mg/L.
The lower the MIC, the more effective the drug. In Europe, a strain is classed as ceftriaxone-resistant once its MIC reaches or exceeds 0.25 mg/L. Below that threshold, standard treatment remains active.
This is threshold reasoning, the same habit you need for most lab values: a number means nothing without its reference range. You apply it every time you read leukocytes on a urine test or a nitrites line, and it is the backbone of any urinalysis interpretation.
A positive test of cure is usually not treatment failure
After treatment for pharyngeal gonorrhea, clinicians often order a test of cure. This is where many patients worry unnecessarily.
A study across four US sexual health clinics covering nearly 2,000 pharyngeal infections found that 4.7 percent of tests of cure came back positive by NAAT. But two thirds of those positives turned out to be reinfection or false positives. Genuine treatment failure accounted for under 1 percent of cases.
A second study, published in 2026, explains why. After treatment, a NAAT at the pharynx can keep detecting DNA from bacteria that are already dead. The test is seeing debris, not an active infection.
What this means for you: never conclude on your own that treatment failed because a follow-up NAAT is positive. Testing too soon, reinfection from an untreated partner, or residual DNA explain most of these results. Only a positive culture confirms a true failure.
Latest scientific advances
Three recent studies show the countermeasure taking shape in laboratories.
Spotting resistance without waiting for culture. Researchers at the UK Health Security Agency validated a PCR assay targeting the penA-60 allele, the most widespread ceftriaxone-resistance mechanism. It runs directly on the clinical specimen, with no need to grow the organism first. In plain terms: a resistance answer in hours rather than days.
Checking that nothing slips through. The GURLS study screened 661 confirmed gonococcal specimens in England looking for resistant strains that surveillance might have missed. It found a single positive, and that case was already known. Reassuring news: the existing net has fine mesh, provided labs keep culturing.
Not forgetting the throat and rectum. Eight years of sentinel surveillance in Singapore identified 23 resistant strains among 2,695 isolates. The authors press two points: keep culture-based surveillance running, and sample extragenital sites. The pharynx is a quiet reservoir where the bacteria swap resistance genes.
A review published in June 2026 by US and UK specialists reaches the same conclusion. The future is neither all-PCR nor all-culture, but both together: rapid molecular assays to guide treatment, and culture to keep the wider view.
What to do in practice
The CDC still recommends ceftriaxone 500 mg intramuscularly as a single dose for people weighing under 150 kg, and has not confirmed a US case of treatment failure due to resistance to recommended therapy. Screening should use NAATs at every anatomic site of sexual exposure.
Three habits worth adopting:
- Tell the clinician about every site of exposure. A urine-only screen does not detect throat or rectal infection.
- If you have symptoms, or a partner with a resistant strain, ask whether a culture can be taken before treatment starts.
- A gonorrhea diagnosis is a reason to check the rest. Start with HIV screening, chlamydia and an RPR syphilis test.
One caution on symptoms: burning on urination points equally to gonorrhea and to an ordinary urinary tract infection. Only the laboratory settles it. A marked inflammatory response may also show up on C-reactive protein.
Frequently asked questions
Has gonorrhea become untreatable?
No. Ceftriaxone still works in the vast majority of European and US cases. Resistant strains remain rare, 23 out of 2,695 isolates in the Singapore series. The goal is early detection.
Should I always ask for a culture?
No. Culture is most useful with persistent symptoms, suspected treatment failure, a partner carrying a resistant strain, or exposure during travel to Southeast Asia.
Why is my test of cure positive?
In roughly two thirds of cases it reflects reinfection or residual DNA rather than failure. Discuss it with your clinician instead of assuming the worst.
Is a urine sample enough?
Not if you have had oral or anal sex. Pharyngeal and rectal infections are often symptom-free and invisible to urine testing.
How long should I wait before a test of cure?
Usually one to two weeks after treatment. Testing earlier risks picking up residual DNA.
Glossary
- NAAT: nucleic acid amplification test. Amplifies bacterial DNA until it is detectable. Highly sensitive, but blind to resistance.
- Culture: growing the organism on a nutrient medium, the prerequisite for susceptibility testing.
- Antimicrobial susceptibility testing: measuring how well each antibiotic works against the isolated strain.
- MIC: minimum inhibitory concentration, in mg/L. European resistance threshold for ceftriaxone is 0.25 mg/L.
- Extragenital site: throat or rectum. Frequently asymptomatic, frequently missed at sampling.
- penA-60: the gonococcal genetic variant behind most ceftriaxone resistance.
Make sense of your results
Lab reports mix abbreviations, units and cut-off values that rarely explain themselves. AI DiagMe helps you decode your test results in plain language, marker by marker, so you walk into your appointment with the right questions.
Sources
- ECDC — Drug-resistant gonorrhoea on the rise in Europe, ECDC warns, July 16, 2026
- ECDC — Upsurge in ceftriaxone-resistant Neisseria gonorrhoeae with evidence of domestic transmission in the EU/EEA and the UK, risk assessment, July 16, 2026
- Euronews — Antibiotic-resistant gonorrhea cases on the rise in Europe, health agency warns, July 20, 2026
- CDC — Gonococcal Infections Among Adolescents and Adults, STI Treatment Guidelines
- Soge OO, Fifer H, Alexander S, Buss SN. Diagnostics and novel laboratory approaches to combat antimicrobial resistance. Expert Rev Mol Diagn. 2026;26(7):587-603. DOI (PubMed)
- Tsai RJ, Cheng L, Tan AL, Yeo BKW. Ceftriaxone-resistant Neisseria gonorrhoeae in Singapore: eight years of sentinel surveillance. Int J STD AIDS. 2026;37(8):833-838. DOI (PubMed)
- Cole MJ, Vickers A, Sun S, et al. What are we missing? Data from the Gonorrhoea Undetected Resistance Laboratory Study (GURLS). Sex Transm Infect. 2026;102(1):32-35. DOI (PubMed)
- Quilter LAS, et al. Routine Pharyngeal Gonorrhea Test-of-Cure: Is It An Effective Cephalosporin-Resistant Gonorrhea Control Strategy? Sex Transm Dis. 2025 (Consensus)
- Adamson P, et al. Cefixime for the Treatment of Neisseria gonorrhoeae Infections in a Setting With Increased Antimicrobial Resistance. Clin Infect Dis. 2026 (Consensus)
- Day M, et al. Molecular detection of ceftriaxone resistance in Neisseria gonorrhoeae clinical specimens. Sex Transm Infect. 2024 (Consensus)
Further reading
- Stool culture test: what the results mean
- HPV self-collection test
- Understanding a normal Pap with a positive HPV test
- High CRP levels: causes, symptoms, treatments
- Complete blood count explained
